Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate?

Lancet Infect Dis. 2023 Dec;23(12):e558-e566. doi: 10.1016/S1473-3099(23)00356-0. Epub 2023 Jul 26.

Abstract

There is increasing debate regarding the harms and benefits of frequent asymptomatic screening for Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men (MSM). One concern is that frequent asymptomatic screening could result in increased antimicrobial resistance in an array of sexually acquired infections and other pathogens, due to selection pressure exerted by frequent broad-spectrum antimicrobial usage within some sexual networks. Here, we outline the harms and benefits of frequent C trachomatis and N gonorrhoeae screening in MSM in high-income settings and propose that screening frequency be reduced. We describe the evidence gaps that should be further explored to better understand the implications of reducing the frequency of asymptomatic C trachomatis and N gonorrhoeae screening in MSM and the surveillance systems that should be in place to prepare for such changes.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents*
  • Chlamydia Infections* / diagnosis
  • Chlamydia Infections* / epidemiology
  • Chlamydia trachomatis
  • Gonorrhea* / diagnosis
  • Gonorrhea* / epidemiology
  • Homosexuality, Male
  • Humans
  • Male
  • Mass Screening
  • Neisseria gonorrhoeae
  • Prevalence
  • Sexual and Gender Minorities*

Substances

  • Anti-Infective Agents